文献速递白血病

S100A16抑制白血病细胞生长与存活并与成人Ph阴性B细胞急性淋巴细胞白血病复发及无复发生存相关

S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2019-03-27

研究比较130例初诊Ph阴性B细胞急性淋巴细胞白血病成人患者与33例健康对照的S100A16转录本水平,在115例达首次完全缓解的患者中分析其与复发及无复发生存的关系,并通过细胞功能实验探讨机制。高S100A16转录本水平者3年累积复发率较低、3年无复发生存率较高,低水平为复发和不良无复发生存的独立相关因素。

要点

  • 初诊Ph阴性B细胞急性淋巴细胞白血病成人患者S100A16转录本水平高于健康对照。
  • 达首次完全缓解者中,高S100A16水平者3年累积复发率较低、无复发生存率较高。
  • 低S100A16转录本水平与较高累积复发率和较差无复发生存独立相关。

核心结论

  • S100A16抑制白血病细胞生长与存活,低S100A16转录本水平与成人Ph阴性B细胞急性淋巴细胞白血病较高复发风险和较差无复发生存独立相关。

研究设计与样本

  • 研究纳入130例初诊成人Ph阴性B细胞急性淋巴细胞白血病患者与33例健康对照,检测S100A16转录本水平。
  • 在115例达首次完全缓解的患者中分析S100A16转录本水平与3年累积复发率及3年无复发生存的关系,并进行多因素分析。
  • 通过敲低和过表达S100A16的B细胞急性淋巴细胞白血病细胞系及异种移植小鼠模型进行功能与信号通路分析。
  • 研究已在中国临床试验注册中心注册(ChiCTR-OCH-10000940)。

主要发现

  • 130例初诊成人Ph阴性B细胞急性淋巴细胞白血病患者S100A16转录本水平高于33例健康对照。
  • 115例达首次完全缓解患者中,高S100A16转录本水平者3年累积复发率为34%[21, 47%],低水平者为40%[48, 72%],P=0.012。
  • 高S100A16转录本水平者3年无复发生存率为65%[53, 78%],低水平者为35%[23, 46%],P=0.012。
  • 多因素分析显示低S100A16转录本水平与较高累积复发率独立相关(HR=3.74[1.01-13.82],P=0.048),与较差无复发生存独立相关(HR=5.78[1.91, 17.84],P<0.001)。
  • 敲低S100A16促进增殖、抗凋亡并降低化疗敏感性,过表达呈相反趋势,异种移植小鼠模型中尤为明显;敲低细胞系中PI3K/AKT上调,过表达细胞系中ERK1/2上调。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refinement of risk stratification in Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukaemia (ALL) might aid the identification of patients who are likely to relapse. Abnormal S100 calcium binding protein A16 (S100A16) has been implicated in various cancers, but its function remains unclear. We found S100A16 transcript levels were higher in 130 adults with newly-diagnosed Ph-negative B-cell ALL compared with 33 healthy controls. In 115 of 130 patients who achieved first complete remission, those with high S100A16 transcript levels displayed a lower 3-year cumulative incidence of relapse (CIR; 34% [21, 47%] vs. 40% [48, 72%]; P = 0·012) and higher 3-year relapse-free survival (RFS; 65% [53, 78%] vs. 35% [23, 46%]; P = 0·012), especially when receiving chemotherapy only. In multivariate analysis a low S100A16 transcript level was independently-associated with a higher CIR (Hazard ratio [HR] = 3·74 [1·01-13·82]; P = 0·048) and inferior RFS (HR = 5·78 [1·91, 17·84]; P < 0·001). Function analysis indicated that knockdown of S100A16 promoted proliferation and anti-apoptosis and reduced chemosensitivity. S100A16 over-expression revealed an opposite trend, especially in a xeno-transplant mouse model. Western blotting analysis showed upregulation of PI3K/AKT and ERK1/2 in S100A16-knockdown and S100A16-overexpression B-cell ALL cell lines respectively. Inhibition assays suggested these two signalling pathways participated in the S100A16-mediated proliferation and survival effects in B-cell ALL cell lines. Trial Registration: Registered in the Chinese Clinical Trial Registry [ChiCTR-OCH-10000940]; http://www.chictr.org.cn.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Lu WY, Zhang JM, et al. S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. Br J Haematol. 2019. PMID: 30916375. doi:10.1111/bjh.15878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。